Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36
- PMID:23306971
- DOI: 10.1007/s11307-012-0609-4
Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36
Abstract
Purpose: [11C]Cimbi-36 was recently developed as an agonist radioligand for brain imaging of serotonin 2A receptors (5-HT2A) with positron emission tomography (PET). This may be used to quantify the high-affinity state of 5-HT2A receptors and may have the potential to quantify changes in cerebral 5-HT levels in vivo. We here investigated safety aspects related to clinical use of [11C]Cimbi-36, including radiation dosimetry and in vivo pharmacology.
Procedures: [11C]Cimbi-36 was injected in rats or pigs, and radiation dosimetry was examined by ex vivo dissection or with PET scanning, respectively. Based on animal data, the Organ Level INternal Dose Assessment software was used to estimate extrapolated human dosimetry for [11C]Cimbi-36. The 5-HT2A receptor agonist actions of [11C]Cimbi-36 in vivo pharmacological effects in mice elicited by increasing doses of Cimbi-36 were assessed with the head-twitch response (HTR).
Results: The effective dose as extrapolated from both rat and pig data was low, 7.67 and 4.88 μSv/MBq, respectively. In addition, the estimated absorbed radiation dose to human target organs did not exceed safety levels. Administration of 0.5 mg/kg Cimbi-36 leads to significant HTR compared to saline, whereas 0.05 mg/kg Cimbi-36 (doses much larger than those given in conjunction with a PET scan) did not elicit a significant HTR.
Conclusions: Administration of tracer doses of [11C]Cimbi-36 does not seem to be associated with unusual radiation burden or adverse clinical effects.
Similar articles
- Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET.Ettrup A, Palner M, Gillings N, Santini MA, Hansen M, Kornum BR, Rasmussen LK, Någren K, Madsen J, Begtrup M, Knudsen GM.Ettrup A, et al.J Nucl Med. 2010 Nov;51(11):1763-70. doi: 10.2967/jnumed.109.074021. Epub 2010 Oct 18.J Nucl Med. 2010.PMID:20956470
- Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers.Ettrup A, Hansen M, Santini MA, Paine J, Gillings N, Palner M, Lehel S, Herth MM, Madsen J, Kristensen J, Begtrup M, Knudsen GM.Ettrup A, et al.Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):681-93. doi: 10.1007/s00259-010-1686-8. Epub 2010 Dec 21.Eur J Nucl Med Mol Imaging. 2011.PMID:21174090
- Characterization of [(11)C]Cimbi-36 as an agonist PET radioligand for the 5-HT(2A) and 5-HT(2C) receptors in the nonhuman primate brain.Finnema SJ, Stepanov V, Ettrup A, Nakao R, Amini N, Svedberg M, Lehmann C, Hansen M, Knudsen GM, Halldin C.Finnema SJ, et al.Neuroimage. 2014 Jan 1;84:342-53. doi: 10.1016/j.neuroimage.2013.08.035. Epub 2013 Aug 28.Neuroimage. 2014.PMID:23994452
- Classics in Neuroimaging: The Serotonergic 2A Receptor System-from Discovery to Modern Molecular Imaging.T L'Estrade E, Hansen HD, Erlandsson M, Ohlsson TG, Knudsen GM, Herth MM.T L'Estrade E, et al.ACS Chem Neurosci. 2018 Jun 20;9(6):1226-1229. doi: 10.1021/acschemneuro.8b00176. Epub 2018 May 15.ACS Chem Neurosci. 2018.PMID:29763291Review.
- 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-[11C]methoxybenzyl)ethanamine.Leung K.Leung K.2011 Feb 18 [updated 2011 Mar 30]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013.2011 Feb 18 [updated 2011 Mar 30]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013.PMID:21473029Free Books & Documents.Review.
Cited by
- Neuroimaging and the Investigation of Drug-Drug Interactions Involving Psychedelics.Wall MB, Harding R, Ertl N, Barba T, Zafar R, Sweeney M, Nutt DJ, Rabiner EA, Erritzoe D.Wall MB, et al.Neurosci Insights. 2024 Oct 8;19:26331055241286518. doi: 10.1177/26331055241286518. eCollection 2024.Neurosci Insights. 2024.PMID:39386147Free PMC article.
- Anin vivo Pig Model for Testing Novel Positron Emission Tomography Radioligands Targeting Cerebral Protein Aggregates.Raval NR, Nasser A, Madsen CA, Beschorner N, Beaman EE, Juhl M, Lehel S, Palner M, Svarer C, Plavén-Sigray P, Jørgensen LM, Knudsen GM.Raval NR, et al.Front Neurosci. 2022 Mar 16;16:847074. doi: 10.3389/fnins.2022.847074. eCollection 2022.Front Neurosci. 2022.PMID:35368260Free PMC article.
- Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.Halberstadt AL.Halberstadt AL.Behav Brain Res. 2015 Jan 15;277:99-120. doi: 10.1016/j.bbr.2014.07.016. Epub 2014 Jul 15.Behav Brain Res. 2015.PMID:25036425Free PMC article.Review.
- New victims of current drug laws.Nutt DJ, King LA, Nichols DE.Nutt DJ, et al.Nat Rev Neurosci. 2013 Dec;14(12):877. doi: 10.1038/nrn3530-c2. Epub 2013 Oct 23.Nat Rev Neurosci. 2013.PMID:24149187No abstract available.
- Correlating the metabolic stability of psychedelic 5-HT₂A agonists with anecdotal reports of human oral bioavailability.Leth-Petersen S, Bundgaard C, Hansen M, Carnerup MA, Kehler J, Kristensen JL.Leth-Petersen S, et al.Neurochem Res. 2014 Oct;39(10):2018-23. doi: 10.1007/s11064-014-1253-y. Epub 2014 Feb 12.Neurochem Res. 2014.PMID:24519542
References
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources